Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital One Financial

Capital One Financial started coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a report released on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $6.00 price objective on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC reiterated a buy rating and issued a $5.00 price target on shares of Heron Therapeutics in a report on Thursday, April 11th. StockNews.com raised shares of Heron Therapeutics from a sell rating to a hold rating in a research note on Tuesday, January 16th.

Heron Therapeutics Trading Up 8.1 %

HRTX stock opened at $2.80 on Tuesday. Heron Therapeutics has a 1-year low of $0.50 and a 1-year high of $3.22. The business’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $1.95. The firm has a market cap of $420.92 million, a PE ratio of -3.26 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.08. The business had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million. On average, analysts forecast that Heron Therapeutics will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP grew its stake in shares of Heron Therapeutics by 127.3% during the 3rd quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock worth $27,515,000 after acquiring an additional 14,963,503 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in Heron Therapeutics by 219.5% during the fourth quarter. Monaco Asset Management SAM now owns 2,226,475 shares of the biotechnology company’s stock worth $3,785,000 after purchasing an additional 1,529,567 shares during the last quarter. Congress Park Capital LLC grew its position in Heron Therapeutics by 205.3% in the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock valued at $3,058,000 after purchasing an additional 1,209,500 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Heron Therapeutics by 100.0% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Tejara Capital Ltd lifted its position in Heron Therapeutics by 28.6% during the 3rd quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after buying an additional 469,548 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.